China Approves Two National Standards for Biochips, Including Disease Susceptibility Gene Testing

Standardisation is the unglamorous plumbing that decides whether a technology stays a lab curiosity or becomes a clinical routine, and the long lead time to 2027 suggests this is groundwork rather than an immediate market event. The scope — terminology plus DNA polymorphism testing methods — points at genetic susceptibility screening, a category where inconsistent assay definitions have historically complicated comparison across labs and platforms. For biochip and microarray suppliers, and for the diagnostics labs that would run such tests, the practical question is whether these standards become the reference point for future regulatory submissions. Whether that adoption materialises is the open question.